Literature DB >> 17722011

No association between common variants in glyoxalase 1 and autism spectrum disorders.

Karola Rehnström1, Tero Ylisaukko-Oja, Raija Vanhala, Lennart von Wendt, Leena Peltonen, Iiris Hovatta.   

Abstract

The autism spectrum disorders (ASDs) are complex diseases with a strong genetic component. Numerous candidate gene studies have tested association between various functional and positional candidate genes and autism, but no common variation predisposing for autism has been identified to date. It has been previously proposed, that glyoxalase 1 (GLO1) might be involved in the pathogenesis of autism as GLO1 protein polarity was significantly changed in the brains of autism patients compared to controls. GLO1 harbors a functional polymorphism that affects the polarity and the enzymatic activity of the protein. In the same study, this polymorphism showed a suggestive association to autism. To investigate whether common variants in GLO1 predispose to autism in the Finnish population, we have genotyped six polymorphisms in GLO1 in families with more than 230 individuals affected with ASDs and carried out both linkage and association analyses. We did not observe significant linkage or association between any SNP and ASDs. Therefore, we suggest that common variants in GLO1 are not significant susceptibility factors for ASDs in the Finnish population. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17722011     DOI: 10.1002/ajmg.b.30582

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

1.  Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity--implications for autism.

Authors:  Madhabi Barua; Edmund C Jenkins; Wenqiang Chen; Salomon Kuizon; Raju K Pullarkat; Mohammed A Junaid
Journal:  Autism Res       Date:  2011-04-12       Impact factor: 5.216

2.  GLO1 gene polymorphisms and their association with retinitis pigmentosa: a case-control study in a Sicilian population.

Authors:  Luigi Donato; Concetta Scimone; Giacomo Nicocia; Lucia Denaro; Renato Robledo; Antonina Sidoti; Rosalia D'Angelo
Journal:  Mol Biol Rep       Date:  2018-08-11       Impact factor: 2.316

3.  Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders.

Authors:  Yeni Kim; Krishna C Vadodaria; Zsolt Lenkei; Tadafumi Kato; Fred H Gage; Maria C Marchetto; Renata Santos
Journal:  Antioxid Redox Signal       Date:  2019-02-01       Impact factor: 8.401

4.  Weak association of glyoxalase 1 (GLO1) variants with autism spectrum disorder.

Authors:  Jernej Kovač; Katarina Trebušak Podkrajšek; Marta Macedoni Lukšič; Tadej Battelino
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-03-27       Impact factor: 4.785

5.  Glyoxalase I activity and immunoreactivity in the aging human lens.

Authors:  Maneesh Mailankot; Smitha Padmanabha; NagaRekha Pasupuleti; Denice Major; Scott Howell; Ram H Nagaraj
Journal:  Biogerontology       Date:  2009-12       Impact factor: 4.277

Review 6.  Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development.

Authors:  Katherine M J McMurray; Margaret G Distler; Preetpal S Sidhu; James M Cook; Leggy A Arnold; Abraham A Palmer; Leigh D Plant
Journal:  Biochem Soc Trans       Date:  2014-04       Impact factor: 5.407

7.  A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior.

Authors:  Richard Williams; Jackie E Lim; Bettina Harr; Claudia Wing; Ryan Walters; Margaret G Distler; Meike Teschke; Chunlei Wu; Tim Wiltshire; Andrew I Su; Greta Sokoloff; Lisa M Tarantino; Justin O Borevitz; Abraham A Palmer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

8.  Role of Glyoxalase 1 (Glo1) and methylglyoxal (MG) in behavior: recent advances and mechanistic insights.

Authors:  Margaret G Distler; Abraham A Palmer
Journal:  Front Genet       Date:  2012-11-19       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.